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Tumor-associated inflammation is a consequence and a driver of tumorigenesis. Three papers in this issue of
Cancer Cell demonstrate the importance of tumor-elicited inflammation in the development and progression
of pancreatic ductal adenocarcinoma and esophageal squamous carcinoma. Disruption of tissue homeo-
stasis culminates in activation of STAT3, generating a pro-tumorigenic inflammatory microenvironment.One hundred and fifty years after its initial
description by Virchow, tumor-associ-
ated inflammation has been recognized
as an important hallmark of cancer (Hana-
han and Weinberg, 2011). Inflammation
contributes to almost every aspect of
tumor development (Grivennikov et al.,
2010). Inflammation’s role in tumor
promotion has been extensively studied,
and recent evidence supports its function
in tumor recurrence and metastasis (Tan
et al., 2011). However, the role of inflam-
matory signals in tumor initiation has
been difficult to address, in part due to
the paucity of adequate experimental
models.
Most inflammatory signals affect
tumorigenesis by activating NF-kB and
STAT3 (Grivennikov et al., 2010). Persis-
tent STAT3 activation in malignant cells
stimulates proliferation, survival, angio-
genesis, invasion, and tumor-promoting
inflammation. Moreover, STAT3 activa-
tion within immune cells enables suppres-
sion of antitumor immunity and promotes
differentiation and recruitment of imma-
ture myeloid cells (iMCs) and tumor-
associated macrophages (TAMs) (Yu
et al., 2009). Although in many cancers
STAT3 is not directly activated by onco-
genic mutations, it exerts critical onco-
genic functions inbothcancerand immune
cells within the microenvironment.
Two papers in this issue demonstrate
that STAT3 activation is essential for initi-
ation and progression of pancreatic
ductal adenocarcinoma (PDAC) (Fukuda
et al., 2011; Lesina et al., 2011). In the
KrasG12D mouse model that develops
pancreatic intraepithelial neoplasia
(PanINs) with high penetrance, with
some of which eventually progresses toPDAC (Hingorani et al., 2003), STAT3 in
pancreatic epithelial cells promotes tumor
development and progression, as its
ablation results in smaller lesions, lower
tumor grade, and fewer metastases.
Importantly, both groups demonstrate
that STAT3 ablation in pancreatic epithe-
lial cells attenuates KrasG12D-induced
PanIN formation, concluding unequivo-
cally that epithelial STAT3 is important
for tumor initiation (Fukuda et al., 2011;
Lesina et al., 2011).
Effects of STAT3 on tumor initiation or
early promotion are likely related to its
ability to control expression of anti-
apoptotic and proliferative genes, thereby
increasing the likelihood that KrasG12D-
expressing cells will survive and
proliferate instead of undergoing onco-
gene-induced senescence or apoptosis.
Indeed, STAT3 in pancreatic epithelial
cells controls expression of Bcl-XL,
Mcl1, survivin, c-Myc, and cyclin D1,
and STAT3 deficiency decreased prolifer-
ation and increased apoptosis (Fukuda
et al., 2011; Lesina et al., 2011). Equally
important is STAT3’s ability to promote
conversion of quiescent adult pancreatic
epithelial cells to cells with a progenitor-
like phenotype upon pancreatitis or other
insults (Fukuda et al., 2011), a process
often referred to as ‘‘acinar-ductal meta-
plasia’’ (ADM). As a result of ADM, more
ductal cells expressing progenitor cell
markers, such as Pdx1 or Hes1, are
formed, and these cells are more suscep-
tible to KRas-mediated transformation
(Murtaugh and Leach, 2007). Chronic
pancreatitis carries increased risk for
pancreatic cancer in humans and signifi-
cantly accelerates KRas-induced tumori-
genesis in mice (Guerra et al., 2007).Cancer CelHence, reprogramming of normal pancre-
atic epithelial cells into progenitors that
can assume a neoplastic fate may be
a key step in PDAC initiation. Importantly,
activation of STAT3 was observed during
pancreatic regeneration in the context of
acute pancreatitis and in KrasG12D-
induced PanIN lesions.
As for STAT3’s role in pancreatic tumor
promotion and progression, several
mechanisms were identified. The first is
the well-described ability of STAT3 to
sustain cell proliferation and block
apoptosis (Lesina et al., 2011). The
second depends on a STAT3 target
gene encoding MMP7, whose ablation in
the pancreas of KrasG12D mice limits
tumor size, progression, and metastasis
but does not affect ADMand PanIN devel-
opment (Fukuda et al., 2011). Other
studies, nevertheless, suggest that
MMP7 may also be involved in early
tumorigenesis, as it is needed for pancre-
atitis and TGFa-induced ADM (Sawey
et al., 2007). Furthermore, epithelial cell
STAT3 orchestrates tumor-associated
inflammation by upregulating chemokines
capable of attracting immune and inflam-
matory cells that further propagate STAT3
activity through production of IL-6, IL-11,
and other cytokines (Fukuda et al., 2011;
Lesina et al., 2011; Yu et al., 2009).
STAT3 ablation in the pancreas prevents
macrophage recruitment during pancrea-
titis and tumor initiation (Lesina et al.,
2011) and decreases total inflammatory
infiltration and expression of proinflam-
matory cytokines during acute pancrea-
titis, which often precedes tumor
development (Fukuda et al., 2011).
The ability of STAT3 to control and
shape the tumor microenvironmentl 19, April 12, 2011 ª2011 Elsevier Inc. 429


































Figure 1. Mechanisms of STAT3-mediated tumorigenesis
(A) Fukuda et al. (2011) suggest that KRas activation drives epithelial cell expression of cytokines, such as
IL-6 and IL-11, which in turn activate STAT3 in an autocrine fashion. STAT3-induced MMP7 is required for
tumor progression but not for tumor initiation, which depends on other STAT3 targets.
(B) Lesina et al. (2011) suggest that epithelial cells harboring active KRas recruit immune cells, particularly
myeloid cells, which produce IL-6 and soluble IL-6R and activate STAT3 in epithelial cells via IL-6 trans-
signaling in a paracrine manner. STAT3 induces antiapoptotic and proproliferative genes, fueling tumor
initiation, promotion, and progression.
(C) Stairs et al. (2011) show that loss of p120-catenin in epithelial cells alters local tissue homeostasis,
generating a protumorigenic microenvironment through the recruitment of iMCs and other immune cells.
Recruitment of these cells is presumably mediated by cytokines and chemokines produced by mutant
epithelial cells, eventually causing activation of Akt, NF-kB, and STAT3 in neoplastic cells.
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STAT3 is activated during pancreatic
tumorigenesis. Fukuda et al. (2011) found
that STAT3 in pancreatic cells directly
affects expression of IL-6 and IL-11,
both of which are STAT3 activating cyto-
kines. Persistent expression of IL-6 or
other STAT3-activating cytokines by
epithelial cells may be responsible for
KRas-induced STAT3 activation. Lesina
et al. (2011), however, suggest that bone
marrow-derived cells, particularly TAMs,
are the major source of STAT3-activating
cytokines during PDAC development.
They found that STAT3 is activated in
cancer cells and stromal cells in the tumor
microenvironment but not in isolated
cancer cell lines, suggesting a non-cell-
autonomous activation of STAT3. Consis-
tent with this, two STAT3 activating
cytokines, IL-6 and LIF, were found to
be robustly produced upon KRas activa-
tion (Lesina et al., 2011). Ablation of IL-6
in KrasG12D mice demonstrated that IL-6
is one of the key STAT3 activators during
PanIN initiation and progression. IL-6
uses two major modes of signaling: clas-430 Cancer Cell 19, April 12, 2011 ª2011 Elssical signaling through ligation of IL-6
receptor (IL-6R) and gp130 on the surface
of the target cell; and trans-signaling
through binding of IL-6 to a soluble form
of IL-6R (sIL-6R), with subsequent binding
of the IL-6-sIL-6R complex to any gp130-
expressing cell. Transgenic mice that
overexpress a circulating sgp130Fc
fusion protein, which inhibits IL-6 trans-
signaling but not classical signaling,
exhibit attenuated KrasG12D-driven PanIN
progression and STAT3 activation in
cancer cells, suggesting that IL-6 trans-
signaling drives PanIN progression (Le-
sina et al., 2011). Conversely, ablation of
the gp130-signaling inhibitor SOCS3
increased STAT3 activation and acceler-
ated PanIN progression (Lesina et al.,
2011). In human PDAC patients, as in
many other cancers, circulating IL-6 is
elevated and STAT3Y705 phosphorylation
is observed in PanIN lesions and acinar
cells in tumor-adjacent tissue. An inter-
esting and important question is whether
SOCS3 expression is downregulated
during PDAC development, as observed
in liver and colon cancers. As in themouseevier Inc.model, myeloid cells and TAMs appear to
be the main sources of IL-6 in human
PDAC (Lesina et al., 2011). In conclusion,
both epithelial and immune cells produce
protumorigenic STAT3-activating cyto-
kines to promote PDAC development
(Figure 1).
The third paper demonstrates how
p120-catenin loss in the oral cavity,
esophagus, and forestomach results in
desmoplasia, a local inflammatory
response, and leads to the development
of squamous esophageal cancer (Stairs
et al., 2011). p120-catenin loss results in
E-cadherin downregulation and activation
of NF-kB, Akt, and STAT3 pathways that
contribute to local inflammation and
tumorigenesis. p120-catenin-deficient
cancer cells secrete GM-CSF, M-CSF,
MCP-1, and TNF, which contribute to
pronounced immune cell infiltration and
create a tumor-promoting microenviron-
ment. Interestingly, the main populations
of immune cells that are recruited to the
microenvironment upon p120-catenin
deletion are Gr1+CD11b+ iMC. The
authors demonstrate that iMCs are protu-
morigenic, due to their effects on cancer
cells and cancer-associated fibroblasts
(CAF). There is no evidence, however,
that iMCs, frequently referred to as
myeloid suppressor cells, are engaged in
immune suppression. It remains largely
unclear how p120-catenin loss leads to
activation of NF-kB, Akt, and STAT3 and
what is the relative contribution of these
distinct pathways to tumorigenesis and
tumor-associated inflammation in this
system. Nevertheless, the recruitment of
iMCs suggests that p120-catenin loss
causes upregulation of chemokines and
cytokines, which may account for tumor-
elicited inflammation (Figure 1).
Altogether, these studies extend our
understanding and appreciation of
tumor-elicited inflammation in cancer
development, and further underscore the
notion that STAT3’s role in cancer
extends beyond its well-appreciated
effects on cell proliferation and survival.
The role of STAT3 activation in immune
cells, particularly myeloid cells, during
PDAC development deserves further
exploration, as does the cause of STAT3
activation in nearly all human PDAC cell
lines, as it has to rely on cell-autonomous
mechanisms.
The paradigm that emerges from these
papers and others is that disrupted tissue
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Previewshomeostasis and integrity, oncogene
activation, or inflammatory insults result
in the induction of chemokines and cyto-
kines that shape the local microenviron-
ment. Recruited immune cells and CAF,
as well as altered epithelial and neoplastic
cells, continue to produce cytokines
(such as IL-6) that activate oncogenic
transcription factors (i.e., STAT3), further
sustaining tumor-associated inflamma-
tion. This paradigm applies not only to
pancreatic or esophageal cancers, but
also to the majority of solid malignancies.
This implies that drugs that disrupt tumor-
associated inflammation, either by target-
ing STAT3 activating kinases (e.g., JAK2)
or key proinflammatory cytokines, such
as IL-6, should have significant thera-
peutic and preventive effects in a variety
of cancers, regardless of their origin.ACKNOWLEDGMENTS
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In this issue of Cancer Cell, Mazzieri, Pucci, and colleagues describe the marked effects of inhibiting the
proangiogenic cytokine, Angiopoietin-2, on tumor angiogenesis and progression in spontaneous tumor
models, as well as the proangiogenic functions of TIE2-expressing macrophages.A number of antiangiogenic agents have
now been developed to inhibit vascular
endothelial growth factor (VEGF) signaling
pathway in tumors. Like the majority
of existing anticancer therapies, their
clinical efficacy is limited by the transient
nature of their inhibitory effects on
advanced tumors. In severalmouse tumor
models, VEGF inhibition results in marked
suppression of tumor angiogenesis, which
often leads to reduced tumor growth and
even tumor shrinkage. However, tumors
usually revascularize and grow back
upon prolonged treatment. This escape
from VEGF blockade is thought to be
due to various mechanisms, including
the upregulation of alternative proangio-genic growth factors, the enhanced inva-
sive/metastatic activity of tumor cells
(to locate an alternative blood supply),
and the increased recruitment of proan-
giogenic bone marrow-derived cells to
the tumor site, where they promote tumor
revascularization andgrowth (Bergers and
Hanahan, 2008).
A major finding in the latter area has
been that certain inflammatory cell types
convey tumor resistance to antiangio-
genic therapies. For example, Shojaei
et al. (2007) showed, in murine tumor
models, that tumor-infiltrating CD11b+
Gr1+myeloid cells can induce tumor resis-
tance to VEGF therapy via their release of
Bv8 (prokineticin-1), a proangiogeniccytokine stimulated by their exposure to
tumor cell-derived granulocyte colony-
stimulating factor (G-CSF). In this way,
certain mouse tumors treated with anti-
VEGF drugs are able to circumvent their
dependency on VEGF and render them-
selves resistant to anti-VEGF therapy.
Proangiogenic myeloid cells are also
thought to be recruited in response to the
elevated release of such chemoattractants
as CXCL12 (stromal cell-derived factor-1,
SDF1) by hypoxic areas of therapy-
damaged tumors (Kioi et al., 2010). Among
the most essential of these are a high-
ly proangiogenic subset of monocytes/
macrophages that express the angio-
poietin receptor, TIE2, and so are termedl 19, April 12, 2011 ª2011 Elsevier Inc. 431
